Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Spain
Spain- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
442 trials match your criteria
Recruiting
Primary progressive multiple sclerosis
RecruitingInvestigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:Spain
Spain- Participants:18–64 years
Recruiting
Dyslipidaemia
RecruitingRegistered drug
Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk
Registered drug
- Disease:Dyslipidaemia
- Substances:Bempedoic AcidObicetrapib
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Bempedoic Acid
Recruiting
Cardiac failure+1
RecruitingInvestigational
Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
Investigational
- Disease:Cardiac failureObesity
- Substances:–
Countries:Spain
Spain- Participants:18–64 years · 65+ years
Recruiting
Breast cancer
RecruitingRegistered drug
Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
Registered drug
- Disease:Breast cancer
- Substances:CarboplatinEribulin Mesylate+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Carboplatin
Recruiting
Pancreatic neuroendocrine tumour
RecruitingRegistered drugNo placebo
A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors
Registered drugNo placebo
- Disease:Pancreatic neuroendocrine tumour
- Substances:EverolimusN-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Everolimus
Recruiting
Cardiovascular disorder+1
RecruitingInvestigational
Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk
Investigational
- Disease:Cardiovascular disorderHypertension
- Substances:ZILEBESIRAN
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:ZILEBESIRAN
Recruiting
Arteriosclerosis
RecruitingInvestigational
Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it
Investigational
- Disease:Arteriosclerosis
- Substances:–
Countries:Spain
Spain- Participants:18–64 years · 65+ years
Recruiting
Bronchiectasis
RecruitingInvestigational
Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis
Investigational
- Disease:Bronchiectasis
- Substances:Bi 1291583
Countries:Spain
Spain- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Bi 1291583
Recruiting
Arteriosclerosis
RecruitingInvestigational
Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease
Investigational
- Disease:Arteriosclerosis
- Substances:Maridebart Cafraglutide
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Maridebart Cafraglutide
Recruiting
Breast cancer
RecruitingRegistered drugNo placebo
Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients
Registered drugNo placebo
- Disease:Breast cancer
- Substances:AbemaciclibAnastrozole+7
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
Recruiting
Cardiac failure
RecruitingRegistered drug
Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction
Registered drug
- Disease:Cardiac failure
- Substances:Bi 690517Empagliflozin
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Bi 690517